Twitter Beğeni Hilesi

For stage III #coloncancer patients “who want to do everything they can” to be cured & reduce recurrence, what to know to help with decision-making around how much chemo to get? Watch 👇📽️! These are hard decisions, but there’s data from #IDEA to help! #CRCTrialsChat Axel Grothey

In this #VideoShort, Dr. Axel Grothey tells us how he decides how much adjuvant chemo his patients need. 📌ctDNA testing may or may not be involved..😜 Watch👇 to learn more. How do you decide the duration of adj chemo for st II & III colon cancer patients in 2024? #CRCTrialsChat

What about duration of adjuvant chemo for Stage II #coloncancer patients? 📌What to keep in mind? 📌High risk vs low risk? 📌Two different SOC treatment options! 📌 What if ctDNA (+)? Watch 👇this #videoShort to learn more! #CRCTrialsChat Axel Grothey

What's new in 2024 for stage II & III colon cancer that you are excited about and why? Hear from Dr Axel Grothey 👇In this #VideoShort And don't miss the very imp message at the end!! youtu.be/_8tdCYc7XNs #CRCTrialsChat #CRCSM

Duration of chemo as part of TNT for stage II & III rectal cancer-- How did we decide on 8 cycles? Watch this #VideoShort to learn more! #LARC #RectalCancer #CRCTrialsChat #CRCSM

Please let me know if the #CRCTrialsChat #VideoShorts on the #IDEA trial and things to consider around duration of adjuvant chemo for stage II & III colon cancer was informative for you. #CRCTrialsChat #VideoShorts will be back next month with a new trial. Have a great weekend!

Bispecific antibodies: advancing precision oncology Trends in Cancer doi.org/10.1016/j.trec… 👉Bispecific antibodies are on the rise with promising data 👏Excellent in depth review ESMO - Eur. Oncology

“EEG abnormalities in #COVID19 patients resemble those observed in early stgs of neurodegenerative diseases, particularly #Alzheimers & related #dementia… neuroinflammation, astrocyte reactivity, hypoxia, & neurovascular injury.”#LongCovid #MedTwitter alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

I hope this systematic review serves as a wake-up call to individuals & countries: #COVID19 is not done w/ us. We should both protect ourselves from repeated infections (😷, 💉, & better air quality), but also view this as a clue in understanding & preventing #dementia.

Don't miss this opportunity for SSO members to advance their research initiatives. We have 4 research grants available this year with two made possible through the generous support from Appendix Cancer PMP Research Foundation. Learn more and apply now! surgonc.org/resources/rese…

RCT in Japan showing NO BENEFIT of adding OX to FP + BEV as 1st line treatment in older adults w/ mCRC The authors did a crude vulnerability survey (VES-13) & admit a more thorough GA would be helpful. Still, this helps inform conversation in the clinic

Another successful study focused on older adults with cancer. In this case, "start low go slow" is a reasonable strategy --no compromise in efficacy --better tolerability --no difference in ability to receive 2nd line therapy Would love to see differences in ability to

Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer ascopubs.org/doi/10.1200/GO… via Hatice Bölek et al

Be sure to check out Dr. Kaysia Ludford present 3-year follow up data in patients with locally advanced dMMR/MSI-H solid tumors treated with pembrolizumab! MD Anderson Cancer Center ESMO - Eur. Oncology #ESMO24

🚨Pleased to share the pre-proof version of the editorial commentary just published ESMO - Eur. Oncology flagship journal Annals of Oncology 👉 Optimizing Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS Precision Oncology 🎯💊💉#Oncology #DrugDevelopment

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 GI Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Dr Joseph McCollom DO 🇺🇸 Erman Akkus 🇹🇷 Gil Morgan, MD 🇺🇸 1141O - Cabozantinib versus placebo for advanced neuroendocrine tumors

Oxaliplatin Addition to Adjuvant ChT in High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis 💥In high-risk stage II CC, adding oxaliplatin to FP does not provide any benefit in terms of OS ❗️An analysis based on MSI status and T4a/b was not performed

Thanks Neeraj Agarwal, MD, FASCO @asco #ASCODailyNews for inviting Samuel Zhang Katelyn Atkins, MD, PHD and I Cancer at Cedars-Sinai to discuss selective omission of #RT in #rectalcancer dailynews.ascopubs.org/do/using-neoad… OncoAlert Alexandra Gangi, MD Manju George MVSc PhD Rectal Cancer Survivor A.n.n. Anthony T. Nguyen, MD, PhD DrKamrava #CRCTrialsChat GI Oncology Now

So many patients receiving oxaliplatin without any benefit!

Management of Locally Advanced Rectal Cancer: ASCO Guideline Clinical Insights 📌The article addresses the challenges clinicians may face in applying the ASCO guidelines for the management of locally advanced rectal cancer ascopubs.org/doi/10.1200/OP…